Bristol Myers Squibb plans to acquire privately held Orbital Therapeutics in a $1.5 billion cash deal as it seeks to bulk up its cell therapy portfolio.
Why it matters: It's the latest deal in which Big Pharma has shelled out cash for a next-generation CAR T-cell therapy.
